Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ventas, Inc. (NYSE: VTR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a healthcare-focused S&P 500 real estate investment trust. Through these filings, investors can review how Ventas reports on its portfolio of approximately 1,400 properties in North America and the United Kingdom, including senior housing communities, outpatient medical buildings, research centers and other healthcare facilities.
Current and historical Forms 8-K offer detailed information about material events affecting Ventas and its subsidiaries. Recent 8-K filings describe items such as the pricing and issuance of senior notes by Ventas Realty, Limited Partnership, amendments to unsecured term loan facilities guaranteed by Ventas, and announcements of quarterly results. These documents help readers understand the company’s capital structure, borrowing arrangements and operating performance disclosures.
Other SEC filings, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, provide broader context on Ventas’s business, risk factors, REIT structure and segment performance. For a healthcare REIT like Ventas, these reports typically include discussions of its senior housing operating portfolio, outpatient medical and research assets, and the demographic and regulatory environment relevant to its properties.
Investors can also use SEC filings to track matters such as dividend practices, debt covenants, and the terms of public offerings or credit agreements. On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections and surface important changes across reporting periods, helping users interpret complex documents more efficiently. Real-time updates from the SEC’s EDGAR system mean that new Ventas filings, including 10-K, 10-Q, 8-K and related exhibits, are available promptly, while Form 4 and other ownership reports can be consulted to analyze insider transactions and equity-based compensation activity associated with VTR.
Ventas, Inc. Chairman and CEO Debra A. Cafaro reported an option exercise and share sale involving the company’s common stock. On 12/01/2025, she exercised 10,322 stock options with an exercise price of $73.71 per share and acquired the same number of common shares. That same day, she sold 10,322 shares of common stock at a weighted average price of $80.5482 per share, in multiple transactions within a price range of $80.13 to $80.81. According to the disclosure, these actions were carried out under a Rule 10b5‑1 trading plan she entered into on March 28, 2024, and involved fully vested options scheduled to expire within the next nine months. After the transactions, Cafaro beneficially owned 1,145,695 shares of Ventas common stock directly and held 30,966 unexercised stock options.
Ventas Realty, Limited Partnership, a wholly owned subsidiary of Ventas, Inc., plans a new senior unsecured notes offering fully and unconditionally guaranteed by Ventas, Inc. The notes will pay fixed semiannual interest from 2025 and will mature on a stated future date, with an option for Ventas to redeem them early at a make‑whole premium and, after a par call date, at 100% of principal plus accrued interest.
The notes will rank equally with other senior unsecured debt and be effectively subordinated to mortgage and other secured borrowings and to obligations of Ventas’s non‑issuer subsidiaries. As of September 30, 2025, Ventas had $12.7 billion of outstanding principal indebtedness, including $2.7 billion of mortgage loans and $1.5 billion of unsecured indebtedness at subsidiaries other than the issuer. Ventas expects to use net proceeds for general corporate purposes, which may include repaying other debt.
Ventas, Inc. insider trading notice: A holder of Ventas common stock has filed a Form 144 to potentially sell 10,322 shares of Ventas, Inc. common stock. The shares are to be sold through Merrill Lynch on the NYSE, with an aggregate market value of $831,418.81, and Ventas had 469,732,824 common shares outstanding. The securities were acquired on 12/01/2025 through a broker-assisted exercise of employee stock options, with payment also on 12/01/2025.
Over the past three months, the same seller, Debra Cafaro, has reported multiple Ventas common stock sales, including 219,515 shares on 10/20/2025 for $15,656,406.48 and 317,258 shares on 10/30/2025 for $23,554,765.13. The notice also includes a representation that the seller is not aware of any undisclosed material adverse information about Ventas’ current or prospective operations.
Ventas, Inc. (VTR) executive Peter J. Bulgarelli, who serves as EVP OM&R-Ventas and President & CEO of LHS, reported open-market sales of company stock on a Form 4. On November 18, 2025, he sold 2,771 shares of common stock at a weighted average price of $80.0074. On November 19, 2025, he sold an additional 2,229 shares at a weighted average price of $80.0827.
The filing states that these transactions were carried out under a Rule 10b5-1 trading plan that he entered into on February 20, 2025, which is a pre-arranged plan for selling shares. Following these sales, Bulgarelli directly beneficially owns 106,488 shares of Ventas common stock.
Ventas, Inc. (VTR) Chair and CEO Debra A. Cafaro reported an option exercise and related share sale. On 11/17/2025, she exercised a stock option to buy 41,294 shares of common stock at an exercise price of $73.71 per share, then sold the same 41,294 shares at a weighted average price of $79.0075 per share. The filing states the transactions were made under a Rule 10b5-1 trading plan entered into on March 28, 2024 and involved options that were fully vested and scheduled to expire in the next 9 months. After these transactions, she directly beneficially owned 1,145,695 shares of common stock and held 41,288 unexercised stock options.
Ventas, Inc. (VTR) insider Peter J. Bulgarelli has filed a Rule 144 notice to sell 2,229 shares of Ventas common stock through Northern Trust Securities, Inc. on the NYSE. The shares have an aggregate market value of $178,504.34 based on the figures in the notice, compared with 469,732,824 Ventas shares outstanding, which is a baseline figure and not the amount being sold.
The shares to be sold were acquired on 02/01/2023 as compensation shares from Ventas, Inc. The filing also lists multiple open-market sales of Ventas securities by Bulgarelli over the prior three months, each with specified share amounts and gross proceeds, indicating an ongoing program of share disposals.
Ventas, Inc. (VTR) reported a planned stock sale by an affiliated holder under a Form 144 notice. The filer intends to sell 2,771 shares of Ventas common stock, with an indicated aggregate market value of $221,700.51, through Northern Trust Securities, Inc. on the NYSE around 11/18/2025. Ventas had 469,732,824 shares outstanding, which is a baseline figure and not the amount being sold.
The securities to be sold were acquired on 02/01/2023 as compensation shares from Ventas. The notice also lists several prior Ventas stock sales by the same seller during the past three months, including transactions such as a sale of 3,924 shares on 11/04/2025 for gross proceeds of $294,286.66. The signer represents that they are not aware of undisclosed material adverse information about Ventas when making or planning these sales.
Ventas, Inc. (VTR) insider Debra Cafaro filed a notice to sell up to 41,294 shares of common stock through Merrill Lynch on the NYSE around 11/17/2025, with an aggregate market value of 3,262,534.21. These shares were acquired the same day via a broker-assisted exercise of employee stock options. The notice also lists prior sales over the past three months, including individual transactions of 219,515, 317,258, and other smaller blocks of common stock, showing a pattern of orderly insider selling.
Ventas, Inc. reported that Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, and President and CEO of Lillibridge Healthcare Services, Inc., is expected to retire effective May 1, 2026. He will remain in his current roles until that date, giving the company time to run a comprehensive search for his replacement. The advance notice is also intended to support an orderly transition of responsibilities to his successor. The company issued a press release on November 17, 2025, to formally announce his planned retirement.
Ventas, Inc. filed a Form 13F reporting its institutional holdings with a Form 13F Information Table value total of $123,788,138. The report lists 1 information table entry, indicates 0 other included managers, and was signed by Carey S. Roberts on 11-14-2025.